Literature DB >> 23021109

Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia.

Katie M Di Sebastiano1, Lin Yang, Kevin Zbuk, Raimond K Wong, Tom Chow, David Koff, Gerald R Moran, Marina Mourtzakis.   

Abstract

Weight loss leading to cachexia is associated with poor treatment response and reduced survival in pancreatic cancer patients. We aim to identify indicators that allow for early detection that will advance our understanding of cachexia and will support targeted anti-cachexia therapies. A total of fifty pancreatic cancer patients were analysed for skeletal muscle and visceral adipose tissue (VAT) changes using computed tomography (CT) scans. These changes were related to physical characteristics, secondary disease states and treatment parameters. Overall, patients lost 1.72 (SD 3.29) kg of muscle and 1.04 (SD 1.08) kg of VAT during the disease trajectory (413 (SD 213) d). After sorting patients into tertiles by rate of VAT and muscle loss, patients losing VAT at > -0.40 kg/100 d had poorer survival outcomes compared with patients with < -0.10 kg/100 d of VAT loss (P= 0.020). Patients presenting with diabetes at diagnosis demonstrated significantly more and accelerated VAT loss compared with non-diabetic patients. In contrast, patients who were anaemic at the first CT scan lost significantly more muscle tissue and at accelerated rates compared with non-anaemic patients. Accelerated rates of VAT loss are associated with reduced survival. Identifying associated features of cachexia, such as diabetes and anaemia, is essential for the early detection of cachexia and may facilitate the attenuation of complications associated with cachexia.

Entities:  

Mesh:

Year:  2012        PMID: 23021109     DOI: 10.1017/S0007114512001067

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  51 in total

1.  Change in Skeletal Muscle Following Resection of Stage I-III Colorectal Cancer is Predictive of Poor Survival: A Cohort Study.

Authors:  Jessica J Hopkins; Rebecca Reif; David Bigam; Vickie E Baracos; Dean T Eurich; Michael M Sawyer
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

Review 2.  Supportive care in pancreatic ductal adenocarcinoma.

Authors:  B Laquente; A Calsina-Berna; A Carmona-Bayonas; P Jiménez-Fonseca; I Peiró; A Carrato
Journal:  Clin Transl Oncol       Date:  2017-06-13       Impact factor: 3.405

Review 3.  Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.

Authors:  Stephanie E Combs
Journal:  Langenbecks Arch Surg       Date:  2015-07-03       Impact factor: 3.445

Review 4.  The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.

Authors:  Hánah N Rier; Agnes Jager; Stefan Sleijfer; Andrea B Maier; Mark-David Levin
Journal:  Oncologist       Date:  2016-07-13

5.  Automated body composition analysis of clinically acquired computed tomography scans using neural networks.

Authors:  Michael T Paris; Puneeta Tandon; Daren K Heyland; Helena Furberg; Tahira Premji; Gavin Low; Marina Mourtzakis
Journal:  Clin Nutr       Date:  2020-01-22       Impact factor: 7.324

6.  Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer.

Authors:  Ana Babic; Michael H Rosenthal; Gloria M Petersen; Brian M Wolpin; William R Bamlet; Naoki Takahashi; Motokazu Sugimoto; Laura V Danai; Vicente Morales-Oyarvide; Natalia Khalaf; Richard F Dunne; Lauren K Brais; Marisa W Welch; Caitlin L Zellers; Courtney Dennis; Nader Rifai; Carla M Prado; Bette Caan; Tilak K Sundaresan; Jeffrey A Meyerhardt; Matthew H Kulke; Clary B Clish; Kimmie Ng; Matthew G Vander Heiden
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-09-18       Impact factor: 4.254

Review 7.  The role of computed tomography in evaluating body composition and the influence of reduced muscle mass on clinical outcome in abdominal malignancy: a systematic review.

Authors:  D J Gibson; S T Burden; B J Strauss; C Todd; S Lal
Journal:  Eur J Clin Nutr       Date:  2015-03-18       Impact factor: 4.016

8.  An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice.

Authors:  Maria Rohm; Michaela Schäfer; Victor Laurent; Bilgen Ekim Üstünel; Katharina Niopek; Carolyn Algire; Oksana Hautzinger; Tjeerd P Sijmonsma; Annika Zota; Dasa Medrikova; Natalia S Pellegata; Mikael Ryden; Agné Kulyte; Ingrid Dahlman; Peter Arner; Natasa Petrovic; Barbara Cannon; Ez-Zoubir Amri; Bruce E Kemp; Gregory R Steinberg; Petra Janovska; Jan Kopecky; Christian Wolfrum; Matthias Blüher; Mauricio Berriel Diaz; Stephan Herzig
Journal:  Nat Med       Date:  2016-08-29       Impact factor: 53.440

9.  Quercetin attenuates cisplatin-induced fat loss.

Authors:  Yi-Chin Lin; Li-Wen Chen; Yun-Chu Chen; Shu-Ting Chan; Jiunn-Wang Liao; Shu-Lan Yeh
Journal:  Eur J Nutr       Date:  2020-08-28       Impact factor: 5.614

10.  Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer.

Authors:  Dietmar Tamandl; Matthias Paireder; Reza Asari; Pascal A Baltzer; Sebastian F Schoppmann; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2015-09-03       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.